Phase I CAR-T Clinical Trials Review

Area of Science:

• Oncology
• Immunotherapy
• Clinical Trial Design

Background:

• Chimeric antigen receptor (CAR) T-cell therapy is a promising cancer treatment.
• Phase I trials are crucial for assessing CAR-T safety and determining maximum tolerated dose (MTD).
• Various dose escalation designs exist, including rule-based, model-based, and model-assisted.

Purpose of the Study:

• To overview the phase I designs employed in current CAR-T clinical trials.
• To identify trends and potential areas for improvement in CAR-T trial methodology.

Main Methods:

• PubMed search for peer-reviewed literature (January 1, 2015 - December 31, 2021).
• Inclusion criteria: human studies, English language, relevant keywords ('CAR-T phase I', 'clinical trials', 'full text').
• Analysis of 109 papers with phase I components.

Main Results:

• Only 31.2% of trials specified a dose escalation design (e.g., 3+3).
• A significant majority (60.6%) did not mention the design used.
• Many studies failed to report cohort size (59.6%) or evaluation timing (19.3%).
• Despite CT.gov registration, only 33.9% posted results.

Conclusions:

• Standardized reporting criteria for phase I CAR-T trials are essential for manuscript quality.
• Adoption of advanced designs (model-based, model-assisted) can enhance CAR-T trial efficiency.
• Improved reporting and design are critical given the rapid development and cost of CAR-T therapy.